Search research articles
Contact Us
Filters
Showing results (211-220 of 277) with videos related to
Page
of 28
Sort By:
Experimental Hematology & Oncology
|
December 30, 2021
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
Kyaw Z Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Scientific Reports
|
May 24, 2022
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
Shuyang Yao, Funda Meric-Bernstam, David Hong, et al.
Clinical Breast Cancer
|
July 29, 2014
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit
Debora de Melo Gagliato, Denis L Fontes Jardim, Gerald Falchook, et al.
Oncotarget
|
November 7, 2014
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab
Gerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Oncotarget
|
May 10, 2014
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms
Jennifer J Wheler, Barbara A Parker, Jack J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2015
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
Funda Meric-Bernstam, Lauren Brusco, Kenna Shaw, et al.
Investigational New Drugs
|
September 25, 2021
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
Kyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Oncotarget
|
April 21, 2017
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas
Roman Groisberg, David S Hong, Vijaykumar Holla, et al.
Advances in Therapy
|
July 9, 2021
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
Renata Ferrarotto, Luana G Sousa, Yun Qing, et al.
Investigational New Drugs
|
July 8, 2022
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors
Filip Janku, Seung-Hoon Beom, Yong Wha Moon, et al.
Page
of 28
Search research articles
Search
Showing results (211-220 of 277) with videos related to
Sort By:
Page
of 28
Experimental Hematology & Oncology
|
December 30, 2021
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
Kyaw Z Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Scientific Reports
|
May 24, 2022
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
Shuyang Yao, Funda Meric-Bernstam, David Hong, et al.
Clinical Breast Cancer
|
July 29, 2014
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit
Debora de Melo Gagliato, Denis L Fontes Jardim, Gerald Falchook, et al.
Oncotarget
|
November 7, 2014
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab
Gerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Oncotarget
|
May 10, 2014
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms
Jennifer J Wheler, Barbara A Parker, Jack J Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2015
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
Funda Meric-Bernstam, Lauren Brusco, Kenna Shaw, et al.
Investigational New Drugs
|
September 25, 2021
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
Kyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Oncotarget
|
April 21, 2017
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas
Roman Groisberg, David S Hong, Vijaykumar Holla, et al.
Advances in Therapy
|
July 9, 2021
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial
Renata Ferrarotto, Luana G Sousa, Yun Qing, et al.
Investigational New Drugs
|
July 8, 2022
First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors
Filip Janku, Seung-Hoon Beom, Yong Wha Moon, et al.
Page
of 28